Companies › Vensica Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 2; Genitourinary; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NT 201 200U Botulinum toxin type A | SNARE | Phase 2 | Overactive Bladder (OAB) | Sep 2027 |
| NT 201 300U Botulinum toxin type A | SNARE | Phase 2 | Overactive Bladder (OAB) | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07553065 | NT 201 200U | Phase 2 | Overactive Bladder (OAB) | Genitourinary | Sep 2027 |
| NCT07553065 | NT 201 300U | Phase 2 | Overactive Bladder (OAB) | Genitourinary | Sep 2027 |
YolTech Therapeutics Cisen Pharmaceutical Levee Medical Urotronic Prokidney
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.